Lupin — 360° view

Lupin, a company in the Pharmaceuticals industry, reported revenue of ₹7,827 crore and net profit of ₹1,155 crore for the September 2026 quarter.

Lupin (NSE: LUPIN) closed at ₹2,014.00 on 20 Nov 2026, down 0.8% over the past year. Its market capitalisation is ₹92,099 crore and it trades at 16.4 times earnings.

Share price
₹2,014.00 (20 Nov 2026)
Market cap
₹92,099 Cr (20 Nov 2026)
P/E
16.35 (20 Nov 2026)
Revenue
₹7,827 Cr (September 2026 quarter)
Net profit
₹1,155 Cr (September 2026 quarter)
ROCE
29.9% (FY26)
ROE
28.7% (FY26)
Book value
₹526 (FY26)
Dividend yield
0.89% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,529.50 / ₹1,892.90 (20 Nov 2026)
1-year return
-0.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: LUPIN

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.